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ABSTRACT
Background. The kidney is always subjected to high metabolic demand. The aim of
this study was to characterizemetabolic profiles of a rat model of chronic kidney disease
(CKD) with cardiorenal syndrome (CRS) induced by prolonged hypertension.
Methods. We used inbred male Dahl salt-sensitive (DS) rats fed an 8% NaCl diet from
six weeks of age (high-salt; HS group) or a 0.3% NaCl diet as controls (low-salt; LS
group).We analyzed function, pathology, metabolome, and the gene expression related
to energy metabolism of the kidney.
Results. DS rats with a high-salt diet showed hypertension at 11 weeks of age and
elevated serum levels of creatinine and blood urea nitrogenwith heart failure at 21weeks
of age. The fibrotic area in the kidneys increased at 21 weeks of age. In addition, gene
expression related to mitochondrial function was largely decreased. The levels of citrate
and isocitrate increased and the gene expression of alpha-ketoglutaratedehydrogenase
and succinyl-CoA synthetase decreased; these are enzymes that metabolize citrate and
isocitrate, respectively. In addition, the levels of succinate and acetyl Co-A, both of
which are metabolites of the tricarboxylic acid (TCA) cycle, decreased.
Conclusions. DS rats fed a high-salt diet were deemed a suitable model of CKD with
CRS. Gene expression and metabolites related to energy metabolism and mitochondria
in the kidney significantly changed in DS rats with hypertension in accordance with the
progression of renal injury.
Subjects Molecular Biology, Cardiology, Nephrology
Keywords Cardiorenal syndrome, Metabolome, Mitochondria, CKD, Rat models, Hypertension
INTRODUCTION
Chronic kidney disease (CKD) is a worldwide public health problem that affects millions
of people worldwide. There has been an increase in the prevalence of CKD in developed
and developing countries. The Global Burden of Disease Study revealed that CKD was
ranked 27th on the list of causes of total number of global deaths in 1990, but rose to
18th in 2010 (Lozano et al., 2012). Patients with CKD have a ten-fold increase in incidence
of cardiovascular death due to common underlying causes of cardiovascular diseases
(Hillege et al., 2000; Lozano et al., 2012; Smith et al., 2006), and impaired renal function is
an independent risk factor for morbidity and mortality in patients with heart failure (HF)
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(Hillege et al., 2000; Smith et al., 2006). Therefore, the term cardiorenal syndrome (CRS)
has been introduced in recent years to characterize this association.
Many risk factors for kidney disease progression have been identified, and poorly
controlled hypertension is a major predictor (Eirin & Lerman, 2013; Nourbakhsh & Singh,
2014; Rubattu et al., 2013). Studies have highlighted several activated deleterious pathways
in the hypertensive kidney. Inflammation, oxidative stress, the renin-angiotension-
aldosterone system (RAAS), and fibrosis are proposed underling mechanisms eliciting
functional decline (Bidani & Griffin, 2004; Eirin & Lerman, 2013). Moreover, in CRS, the
same deleterious pathways develop vicious cycle, which CKD and HF exacerbate each other
(Rubattu et al., 2013). However, the precise molecular mechanisms responsible for renal
injury in CRS have not been fully elucidated. The kidney is a highly energetic organ that
is richly perfused. Renal blood flow (RBF) normally accounts for approximately 25% of
cardiac output. The renal oxygen consumption per gram of tissue is the second-highest
compared to that of other organs, with cardiac oxygen consumption being the highest
(Nourbakhsh & Singh, 2014). This is largely driven by the high RBF since the renal oxygen
extraction is low mitochondrial homeostasis is critical for the maintenance of normal
kidney function, including the production of cellular energy and the regulation of reactive
oxygen species. Thus, metabolic protection against acute kidney injury has been intensively
investigated, such as activators of mitochondrial biogenesis and ROS modulators (Ishimoto
& Inagi, 2016). However, there are few studies that have explored the influence ofmetabolic
changes of CKD in CRS.
The Dahl salt-sensitive (DS) rat is a useful model system for understanding salt-induced
hypertension, since these rats exhibit marked hypertension when they are fed a high-salt
diet (Inoko et al., 1994; Kato et al., 2010). Specifically, when the rats are fed a high-salt diet,
they develop hypertension and subsequently develop HF at approximately 18 weeks of age
(Kato et al., 2010). The DS rats fed a high-salt diet also show an increase of serum creatinine
and urinary protein expression related to kidney injury at approximately 10 weeks, and can
be used as a model of CKD (Hisaki et al., 2005; Nishiyama et al., 2004). The purpose of the
present study was-to characterize the change of renal metabolic profiles using DS rats with
hypertension at 21 weeks of age, which is the end stage of CKD and HF. This was done to
gain insight into potential therapeutic targets for CKD in CRS.
METHODS
Animals
Animal care and experiments were approved by the Institutional Animal Care and Use
Committee of Kyoto University (MedKyo 14183) and conducted following the Guide for
Care and Use of Laboratory Animals published by the United States National Institutes of
Health. Inbred male DS rats (Japan SLC, Hamamatsu, Shizuoka, Japan) were fed a 0.3%
NaCl (low-salt; LS) diet until the age of 6 weeks, after which they were fed an 8% NaCl
diet (high-salt; HS) (Inoko et al., 1994; Kato et al., 2010; Kawamoto et al., 2015). The rats in
the current study were the same animals used in our previous report (Tanada et al., 2015).
Therefore, the characterization of hemodynamics in these rats has already been reported.
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Protocols
DS rats fed only an LS diet (LS group) were used as controls, and DS rats fed an HS diet (HS
group) were used as a model of renal failure. There were four groups of rats categorized
by the amount of salt in the diet (LS or HS) and week of sacrifice (11 weeks or 21 weeks):
the 11-week-old LS group (n= 8), 11-week-old HS group (n= 8), 21-week-old LS group
(n= 12), and 21-week-old HS group (n= 11). Serial measurements of heart rate and blood
pressure were performed every two weeks from the age of 11 weeks until sacrifice at 21
weeks.
Blood and tissue sampling
The rats were anesthetized with inhaled diethyl ether (Wako Pure Chemical Industries,
Osaka, Japan) and sacrificed by decapitation without fasting. Blood samples were collected
via the right atrium in tubes and centrifuged at 1,500 rpm for 10 min, and blood serum was
taken from the supernatant. Measurement of serum creatinine and blood urea nitrogen
(BUN) was entrusted to SRL Inc. (Kyoto, Japan). Both kidneys were rapidly removed, snap
frozen in liquid nitrogen, and stored at−80 ◦C or fixed with 4% paraformaldehyde (PFA).
Cardiac echocardiography
Transthoracic echocardiography was performed as previously reported (Kato et al., 2010).
Rats were anesthetized briefly with inhaled diethyl ether (Wako Pure Chemical Industries,
Osaka, Japan), and transthoracic echocardiography was performed using a Sonos-5500
echocardiograph (Agilent Technologies, Santa Clara, CA, USA) with a 15-MHz linear
transducer. Intraventricular septal thickness (IVSd), left ventricular dimension in the
diastolic phase (LVDd), and left ventricular dimension in the systolic phase (LVDs) were
measured with M-mode echocardiography, and fractional shortening (FS) was calculated.
Quantitative reverse transcription-polymerase chain reaction
Total RNA was isolated from the kidneys in each group by the acid guanidinium
thiocyanate-phenol-chloroform method. Quantitative reverse transcription-polymerase
chain reaction (RT-PCR) was performed as in previous reports (Inuzuka et al., 2009;
Niizuma et al., 2012). The oligonucleotide primers are listed in Table S1. ThemRNA level of
each genewas standardized using the expression level of the 18S ribosomal RNAas a control.
Fibrosis of the kidneys
The kidneys were fixed in 4% PFA, embedded in paraffin, and sectioned for histological
evaluation. The fibrotic area was quantified in tissue sections with Sirius Red staining, as
previously described (Okuda et al., 2013).
Metabolomic analysis of the kidneys
The kidneys were subjected to metabolomic analysis as described previously (Kato et al.,
2010) using capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) (Soga
et al., 2003). Briefly, frozen kidney tissues were immediately plunged intomethanol (0.5ml)
containing internal standards (300 µM each of methionine sulfate for cations and MES for
anions) and homogenized for 3 min to inactivate enzymes. 200 µl of deionized water and
500 µl of chloroform were added, and the mixture was thoroughly mixed. The solution
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was centrifuged at 15,000 rpm for 15 min at 4 ◦C and the 600 µl upper aqueous layer
was filtered centrifugally through a Milipore-5 kDa cutoff filter to remove proteins. All
CE-TOFMS was performed using an Agilent CE capillary electrophoresis system (Agilent
Technologies, Santa Clara, CA). We measured the levels of metabolites in glycolysis and
the tricarboxylic acid (TCA) cycle, and amino acids and their derivatives.
Western blotting
Western blotting of kidney tissues was performed as described previously (Tanada et al.,
2015). The primary antibodies used forWestern blottingwere as follows: NDUFA9 (1:1,000,
Santa Cruz, Dallas, TX, USA) and GAPDH (1:1,000; Cell Signaling, Danvers, MA, USA).
Statistical analysis
Values are expressed as means ± the standard error of the mean (SEM). ANOVA was
used for comparisons multiple groups. In all tests, a value of p< 0.05 was considered
statistically significant.
RESULTS
Dahl salt-sensitive rats fed a high-salt diet show a high heart rate,
systolic blood pressure, and cardiac dysfunction
As we previously reported (Tanada et al., 2015), DS rats fed an HS diet (HS group)
developed hypertension, showed cardiac dysfunction, and died from heart failure. DS rats
fed an LS diet (LS group) did not develop hypertension, and were used as controls. The
heart rate was significantly higher in the HS group compared to the LS group from 11 weeks
of age to 19 weeks of age (Fig. S1A). Conversely, systolic blood pressure was significantly
higher in the HS group compared to LS group from 11 weeks of age to 21 weeks of age
(Fig. S1A). At 21 weeks of age, intraventricular septal thickness (IVSd) increased in the
HS group on echocardiographic examination. In addition, left ventricular dimension in
the diastolic phase (LVDd) increased, and fractional shortening (FS) decreased in the HS
group compared to that of the LS group (Fig. S1B).
The HS group had a high concentration of serum creatinine and
blood urea nitrogen at 21 weeks of age
There was no significant difference in the concentration of serum creatinine or BUN
between the LS group and HS group at 11 weeks of age (Fig. S1B). However, the HS group
showed a significantly higher concentration of both creatinine and BUN compared to the
LS group at 21 weeks of age (Fig. S1C).
Fibrosis in the kidney and gene expression related to the
glomerulus, renal tubules, and fibrosis
At 21 weeks of age, the area of fibrosis in the kidney was significantly increased in the HS
group compared to the LS group. There was no difference between the HS and LS groups
at 11 weeks of age (Figs. S2A and S2B).
Nephrin and podocin are extracellular components of the slit diaphragm coded by
Nphs1 andNphs2, respectively (Boute et al., 2000; Ruotsalainen et al., 1999). The expression
ofNphs1was significantly decreased in the HS group compared to the LS group at 21 weeks
Tanada et al. (2017), PeerJ, DOI 10.7717/peerj.3352 4/19
Figure 1 Gene expression related to the glomerulus, renal tube, and fibrosis. (A) NPHS1. (B) NPHS2.
(C) KIM1. (D) NGAL. (E) Osteopontin. (F) Collagen 1. (G) αSMA. At 11 weeks of age, the expressions of
Kim1, Ngal, osteopontin, and collagen 1 were significantly increased in the HS group compared to the LS
group. At 21 weeks of age, the expression of Nphs1 significantly decreased in the HS group compared to
the LS group. Conversely, the expressions of Nphs2, Kim1, Ngal, osteopontin, collagen 1, and αSMA sig-
nificantly increased in the HS group compared to the LS group. LS-11 week, n = 8; LS-21 week, n = 12;
HS-11 week, n= 8; HS-21 week, n= 11. ∗p< 0.05 versus LS-C group; †p< 0.05 versus rats at 11 weeks of
age.
of age (Fig. 1A). Though the expression of Nphs2 decreased in the HS group at 21 weeks of
age compared to 11 weeks of age, there was no difference between the HS and LS groups
at 21 weeks of age (Fig. 1B).
The gene expression of kidney injury molecule-1 (Kim1) indicates the degree of
interstitial fibrosis, renal tubular damage, and inflammation (Van Timmeren et al., 2006).
Neutrophil gelatinase–associated lipocalin (NGAL) is also associated with renal tubular
damage in ischemic or inflammatory responses (Mori et al., 2005). In the present study, the
expression of Kim1 and Ngal was significantly higher in the HS group than the LS group at
both 11 and 21 weeks of age (Figs. 1C and 1D). In addition, in the HS group, the expression
of these genes was significantly increased at 21 weeks of age compared to 11 weeks of age
(Figs. 1C and 1D).
The expression of the osteopontin gene increases in rat renal fibroblasts with aldosterone
(Irita et al., 2008) and in the kidneys of hypertensive rats (Blasi et al., 2003). Similarly, the
expression of type 1 collagen (collagen 1) and α-smooth muscle actin genes (αSMA)
increases in renal fibrosis (Lekgabe et al., 2005; Wang et al., 2008). In the present study,
expression of these genes was significantly higher in the HS group than the LS group
at both 11 and 21 weeks of age (Figs. 1E–1G). The expression of these genes increased
significantly at 21 weeks of age compared to 11 weeks in the HS group only (Figs. 1E–1G).
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Gene expression related to mitochondrial function, glycolysis, and
free fatty acid metabolism in the kidneys
We examined the expression level of some genes related to mitochondrial function,
glycolysis, and fatty acid metabolism at 11 and 21 weeks of age. Gene expression related to
glycolysis was measured, and the expression of hexokinase (Hk) 1 and Hk2, which catalyze
the transfer from glucose to glucose-6-phosphate (G6P), significantly increased in the
HS group compared to the LS group at 21 weeks of age. Conversely, the expression of
Tp53-induced glycolysis and apoptosis regulator (TIGAR), which alters the concentration
of fructose 2,6-bisphosphate (Bensaad et al., 2006), was significantly decreased in the HS
group compared to the LS group at 21 weeks of age (Table 1).
Peroxisome proliferator-activated receptor γ coactivator1-α (PGC1-α) is a master
regulator of mitochondrial biogenesis, though there was no change between the LS and HS
group (Table 1 and Fig. 2A). Proliferator activated receptor α (PPARα), nuclear respiratory
factor 1 (NRF1), and NRF2 are related to mitochondrial biogenesis. Pparα expression was
significantly decreased and Nrf1 expression was significantly increased in the HS group
compared to the LS group at 21 weeks of age. Otherwise, compared to that in the LS group,
Nrf2 expression was significantly increased at 11 weeks of age and decreased at 21 weeks of
age in the HS group (Table 1 and Fig. 2).
Subsequently, wemeasured the expression of genes related to oxidative phosphorylation.
Though uncoupling protein 3 (UCP3) is known for uncoupling ATP synthesis from
oxidative metabolism, its transcription is regulated by PPARα (Young et al., 2001). In this
study, like Pparα expression, Ucp3 expression decreased significantly in the HS group
compared to the LS group at 21 weeks of age. The expression levels of several genes related
to the respiratory chain also changed in the HS group; NADH dehydrogenase 4 (Nd4),
alpha-subcomplex 9 (αS9), succinate dehydrogenase b (Sdhb) and cytochrome-c (Cyt-c)
expression significantly decreased in the HS group from that in the LS group at 21 weeks of
age. Conversely, in the HS group, expression of cytochrome c oxidase 1 (Cox1) decreased
at 11 weeks of age and increased at 21 weeks of age, and Cox4 increased significantly at 21
weeks of age (Table 1 and Fig. 2).
Medium-chain acyl-CoA dehydrogenase (MCAD) is an enzyme related to fatty acid
oxidation, and its expression decreased significantly in the HS group compared to the LS
group at 21 weeks of age. ATP-binding cassette sub-family A member 1 (ABCA1) has a
critical role in cellular cholesterol and phospholipid efflux, and its gene expression was
significantly increased in the HS group compared to the LS group at 21 weeks of age
(Table 1).
Metabolomic profile of the kidney
To examine energy metabolism in renal damage, we performed a comprehensive
metabolomic analysis. The results of the quantification showed metabolites related to gly-
colysis, including the TCA cycle, and amino acids and their derivatives (Fig. 3 and Table S3).
By two-way ANOVA analysis, we assessed the significance (p value) for time (11 weeks
and 21 weeks) and treatment effects (LS diet and HS diet). The metabolites that were not
significantly different (p≥ 0.05) regarding time or interaction effects are only represented
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Table 1 Gene expression quantified by real-time RT-PCR in kidney.
11 week High-salt
Low-salt High-salt Low-salt High-salt
Numbers of animals 8 12 8 11
Glycolysis
Glut1 1.00± 0.08 1.07± 0.07 0.90± 0.07 1.22± 0.12
Glut4 1.00± 0.15 2.43± 0.43* 2.41± 0.65 2.64± 0.49
HK1 1.00± 0.10 1.11± 0.08 0.83± 0.04 1.93± 0.23**
HK2 1.00± 0.21 1.14± 0.07 0.99± 0.12 2.11± 0.18**
PFK 1.00± 0.11 1.00± 0.07 0.83± 0.05 0.84± 0.06
GAPDH 1.00± 0.24 0.97± 0.10 1.15± 0.13 1.05± 0.17
PGAM2 1.00± 0.27 1.02± 0.10 1.07± 0.11 0.91± 0.13
TIGAR 1.00± 0.06 1.01± 0.37 0.98± 0.05 0.69± 0.04**
HIF-1α 1.00± 0.11 1.01± 0.04 1.00± 0.10 1.21± 0.11
ACLY 1.00± 0.11 0.98± 0.05 0.84± 0.06 0.94± 0.08
Fatty acids
ACS 1.00± 0.15 0.96± 0.10 0.78± 0.06 0.79± 0.09
CPT-1 1.00± 0.33 0.64± 0.11 0.62± 0.17 0.44± 0.10
ACCα 1.00± 0.15 1.01± 0.07 0.90± 0.09 1.21± 0.14
ACCβ 1.00± 0.09 0.90± 0.08 1.06± 0.10 0.90± 0.11
FAT/CD36 1.00± 0.14 1.19± 0.07 1.03± 0.09 1.42± 0.15
VLCAD 1.00± 0.23 0.81± 0.09 0.82± 0.13 0.58± 0.07
LCAD 1.00± 0.29 0.89± 0.11 1.01± 0.14 0.84± 0.15
MCAD 1.00± 0.06 1.09± 0.04 1.02± 0.06 0.66± 0.58**
ABCA1 1.00± 0.12 1.11± 0.07 0.89± 0.03 1.65± 0.13**
SREBF1 1.00± 0.17 0.78± 0.05 0.92± 0.11 0.73± 0.08
SREBF2 1.00± 0.26 0.83± 0.09 0.96± 0.14 0.79± 0.11
Mitochondrial function
PGC1α 1.00± 0.10 0.85± 0.03 0.95± 0.06 1.04± 0.07
PPARα 1.00± 0.12 0.90± 0.06 1.11± 0.08 0.78± 0.09**
NRF1 1.00± 0.10 0.85± 0.02 0.86± 0.04 1.18± 0.07**
NRF2 1.00± 0.08 0.71± 0.05* 0.72± 0.03 0.84± 0.04**
TFAM 1.00± 0.04 1.03± 0.03 0.98± 0.08 1.00± 0.05
UCP3 1.00± 0.04 1.13± 0.04* 1.19± 0.08 0.89± 0.03**
ANT 1.00± 0.17 1.00± 0.18 1.12± 0.23 0.94± 0.16
SDHB 1.00± 0.05 1.10± 0.05 0.97± 0.07 0.79± 0.04**
αS9 1.00± 0.03 0.97± 0.02 0.93± 0.02 0.70± 0.04**
ND4 1.00± 0.10 0.80± 0.02* 0.92± 0.03 0.65± 0.04**
Cyt-b 1.00± 0.24 0.77± 0.12 0.55± 0.19 0.61± 0.17
Cyt-c 1.00± 0.28 1.09± 0.15 1.06± 0.20 0.78± 0.27**
COX1 1.00± 0.12 0.85± 0.04 0.92± 0.05 0.68± 0.07**
(continued on next page)
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Table 1 (continued)
11 week High-salt
Low-salt High-salt Low-salt High-salt
COX4 1.00± 0.07 1.01± 0.03 1.01± 0.05 0.80± 0.06**
COX5a 1.00± 0.15 1.08± 0.10 1.31± 0.18 1.08± 0.19
Notes.
Glut, Glucose transporter; HK, hexokinase; PFK, phosphofructokinase; GAPDH, glyceraldehyde-3-phosphate dehydro-
genase; PGAM, phosphoglycerate mutase; TIGER, TP53 induced glycolysis regulatory phosphatase; HIF-1α, Hypoxia In-
ducible Factor 1-α; ACLY, ATP citrate lyase; ACS, Acyl-CoA synthetase; CPT-1, Carnitine palmitoyltransferase-1; ACC,
Acetyl-CoA Carboxylase; FAT/CD36, fatty acid translocase/cluster of differentiation 36; VLCAD, very-long-chain acyl-CoA
dehydrogenase; LCAD, long-chain acyl-CoA dehydrogenase; MCAD, medium-chain acyl-CoA dehydrogenase; ABCA1,
ATP-Binding Cassette 1; SREBF, sterol regulatory element binding transcription factor; PGC1-α, peroxisome proliferator-
activated receptor γ coactivator1-α; PPARα, peroxisome proliferator-activated receptor α; NRF, nuclear respiratory factor;
TFAM, mitochondrial transcription factor A; UCP3, uncoupling protein 3; ANT, adenine nucleotide translocator; SDHB,
succinate dehydrogenase b; αS9, alpha-subcomplex 9; ND4, NADH dehydrogenase 4; Cyt, cytochrome; COX, cytochrome
c oxidase.
Values are the mean± SEM.
*p< 0.05 versus Low-salt 11 week.
**p< 0.05 versus Low-Salt 21 week.
Red indicates the increase; blue indicates the decrease.
by the bar plots of 21-week-old rats. Other metabolites are represented by bar plots of
11-week-old and 21-week-old rats (Fig. 3). The metabolites of kidney tissue significantly
changed in the HS group from that in the LS group. Especially, the increased urea and
creatinine levels at 21 weeks of age validated that the metabolome analysis was performed
successfully.
The levels of 2,3-diphosphoglycerate (2,3-DPG) and phosphoenolpyruvate (PEP),
intermediate metabolites of glycolysis, decreased in the HS group at 21 weeks of age. The
levels of several amino acids and derivatives such as serine, betaine, alanine, histidine,
citruline, proline, arginine and putrescine, increased in the HS group at 21 weeks of age.
On the contrary, taurine, β-alanine, and glutamate were decreased in the HS group at
21 weeks of age. Levels of several metabolites in the TCA cycle also changed; the levels of
citrate, cis-acotinate and isocitrate increased, and the levels of succinate and acetyl CoA
decreased (Fig. 3 and Table S3).
Subsequently, we measured the gene expression of enzymes that are involved in the TCA
cycle (Fig. 4): aconitase is encoded by Aco2, which catalyzes the reversible isomerization of
citrate and isocitrate; 2-oxoglutarate dehydrogenase (OGDH) is an enzyme that catalyzes
the oxidation of 2-oxoglutarate; succinyl-CoA synthetase (SCS) is encoded by the gene
Suclg1, and is an enzyme that hydrolyzes succinyl-CoA into succinate and CoA-SH;
fumarate hydratase is encoded by the Fh gene and is the enzyme that catalyzes the hydration
of fumarate to malate. The gene expression of Aco2, Ogdh, Suclg1, and Fh was significantly
decreased in the HS group compared to the LS group at 21 weeks of age (Fig. 4).
Furthermore, the amounts of nicotinamide adenine dinucleotide (NAD+) and NADH
were measured on metabolome analysis. NAD+ plays a central role in cellular energy
metabolism and energy production. The NAD+/NADH ratio is often considered as the
key of mitochondrial function. Cytoplasmic NAD+/NADH ratios range between 60 and
700, and mitochondrial NAD+/NADH ratios are maintained at 7–8 (Stein & Imai, 2012).
The reduction of NAD+/NADH ratio has been reported in renal injuries in a type 1
diabetic mouse model (Zhu et al., 2014). In the present study, both NAD+ and NADH
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Figure 2 Gene expression related to mitochondrial function. (A) PGC1-α. (B) PPARα. (C) SDHB.
(D) αS9. (E) COX1. (F) COX4. At 11 weeks of age, the expression of COX4 was significantly decreased
in the HS group compared to the LS group. At 21 weeks of age, the expressions of PPARα, SDHB, αS9,
COX1, and COX4 significantly decreased in the HS group compared to the LS group. LS-11week, n = 8;
LS-21week, n= 12; HS-11week, n= 8; HS-21week, n= 11. ∗p< 0.05 versus LS-C group; †p< 0.05 versus
rats at 11 weeks of age.
levels significantly decreased at 21 weeks of age, while NAD+/NADH ratio showed no
change between the HS group and LS group (Fig. S3B). It is well known that mitochondrial
Complex I catalyzes the first step of NADH oxidation, and increases the NAD+/NADH
ratio. Therefore, we measured the protein expression of NADH dehydrogenase ubiquinone
1 α subcomplex subunit 9 (NDUFA9), a subunit of mitochondrial Complex I, at 21 weeks
of age, because the level of mRNA expression of NDUFA9 (αS9) was significantly decreased
in the HS group (Table 1 and Fig. 2D). However, there was no significant change between
the LS group and HS group (Fig. S3B).
DISCUSSION
Consistent with previous reports (Hisaki et al., 2005; Karlsen et al., 1997; Kato et al., 2010;
Rapp & Dene, 1985), DS rats fed an HS diet showed high blood pressure, an increased
concentration of serum creatinine and BUN, and an increased fibrotic zone in their
kidneys at 21 weeks of age. We demonstrated that the metabolites levels in the first half of
the TCA cycle increased; the level of succinate in the latter half of the TCA cycle decreased
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Figure 3 Metabolites in kidney tissue. After assessing the p value for the time effect (11 weeks and 21
weeks) and the treatment effect (LS diet and HS diet), the metabolites that were not significantly different
(p ≥ 0.05) regarding time or interaction effect are only represent by bar plots of 21-week-old rats. Other
metabolites are represented by bar plots of 11-week-old and 21-weeks-old rats. In the HS group at 21
weeks of age, the levels of 2,3-diphosphoglycerate (2,3-DPG) and phosphoenolpyruvate (PEP), intermedi-
ate metabolites of glycolysis, decreased. The levels of several amino acids and their derivatives also changed
in rats in the HS group at 21 weeks of age. The amount of urea, creatinine, and citrulline increased at 21
weeks of age. The levels of several metabolites in the TCA cycle also changed; the levels of citrate and isoc-
itrate increased while that of succinate and acetyl CoA decreased. LS-11 week, n = 8; LS-11 week, n = 12;
HS-11 week, n= 8; HS-21 week, n= 11.
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Figure 4 Gene expression of enzymes in the TCA cycle. (A) CS. (B) Aco2. (C) OGDH. (D) Sulg1.(E) Fh.
(F) MDH2. The expressions of Aco2, Ogdh, Suclg1, and Fh significantly decreased in the HS group at 21
weeks of age. These results indicate mitochondrial dysfunction related to the TCA cycle. LS-11week, n= 8;
LS-21week, n= 12; HS-11week, n= 8; HS-21week, n= 11 ∗p< 0.05 versus LS-C group; †p< 0.05 versus
rats at 11 weeks of age.
in DS rats in CKD with CRS, and the gene expression related to energy metabolism also
significantly changed.
The DS rats fed a high-salt diet showed an increase in urinary protein expression and
serum creatinine levels, and a decrease in creatinine clearance. They also exhibited injured
glomeruli characterized by sclerosis enlarged glomerular size, and severe tubulointerstitial
fibrosis on histochemical analysis (Du et al., 2009). Moreover, DS rats treated with
vasopressin type 2 receptor antagonist showed an improvement in cardiac dysfunction and
kidney dysfunction simultaneously (Ishikawa et al., 2013;Morooka et al., 2012). Treatment
with the calcium sensitizer and the AT1-receptor antagonist in DS rats also ameliorate
cardiac dysfunction and kidney injury simultaneously (Biala et al., 2011). We showed a
close correlation among systolic blood pressure, cardiac dysfunction, and renal damage.
These findings suggested that the DS rat is a useful model of CKD with CRS. Although
this model did not fully recapitulate human hypertensive renal disease, the Dahl rat model
nevertheless may have many advantages in preclinical studies for determination of suitable
candidates for biomarker and drug discovery.
In the present study, the metabolic profiles in kidney tissues revealed increased levels
of citrate and isocitrate, decreased gene expression of Ogdh and Scs, which are enzymes
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that metabolize citrate and isocitrate, respectively, and decreased levels of succinate and
acetyl CoA, components of the TCA cycle. This profile consisting of mostly decreased
gene expression related to mitochondrial function, indicated mitochondrial dysfunction in
both hypertension and long-lasting hypertension. Zheleznova et al. (2012) reported oxygen
deficiencies in DS rats using mitochondrial proteomic analyses; mitochondrial protein
expression was depressed with decreased oxygen utilization in the renal medullary thick
ascending limb of the Dahl rats. Renal mitochondrial damage has also been reported in
various models of hypertension, such as the spontaneous hypertension rat, 2-kidney/1-clip
model rat, ischemia/reperfusion injury, and renal hypertension in pigs (Eirin, Lerman
& Lerman, 2015). Therefore, mitochondrial damage may be the hallmark of CKD due
to hypertension. In patients with kidney disease, urine metabolomics have revealed that
metabolites linked tomitochondria are consistently decreased in the human diabetic kidney
(Sharma et al., 2013). Others have also reported the downregulation of genes related to
oxidative metabolism in patients with CKD on peritoneal dialysis (Zaza et al., 2013).
The mechanism underling the renal mitochondrial damage in Dahl rat was not
determined in the present study. Hypertension is commonly associated with mechanical
stretch, increased production of ROS, and extracellular matrix turnover and fibrosis, which
in turn alter the structure and function of cellular organelles including mitochondria. In
Dahl rats, enhancedROSproductionhas beendetected in various organs of salt hypertensive
Dahl rats including the kidney (Trolliet, Rudd & Loscalzo, 2001; Vokurkova et al., 2015),
heart (Kato et al., 2010), liver (Kato et al., 2012), and blood vessels (Swei et al., 1997;Trolliet,
Rudd & Loscalzo, 2001). In addition, serum concentrations of pro-inflammatory cytokines
are also elevated (Kato et al., 2012). These factors may contribute to the development of
mitochondrial dysfunction, which in turn causes podocyte injury, tubular epithelial cell
damage, and endothelial dysfunction (Che et al., 2014). Mitochondrial dysfunction also
stimulates TGF-β signaling and fibrosis through mitochondrial-derived ROS (Che et al.,
2014; Jain et al., 2013).
There are two clinical implications of the present study. First, its use for biomarker
development should be mentioned. Metabolites changed as the disease progressed.
Therefore, metabolites in blood and urine samples could be candidates for a biomarker
for the early detection of CKD or the prediction of worsening disease (Cisek et al., 2016;
Sharma et al., 2013; Zaza et al., 2013). The second implication is the development of
therapeutic targets. Though it remains unclear how renal dysfunction cause abnormal
metabolic status in mitochondria, the mitochondria could also be a target of therapy
for hypertensive kidney disease (Che et al., 2014; Ishimoto & Inagi, 2016). For example,
activation of PGC1α using a transgenic model prevented acute kidney injury (Tran et al.,
2011). In addition, quinone analogues such as MitoQ are mitochondrial ROS modulators
and other antioxidants such as omega-3 polyunsaturated fatty acids, N-acetylcysteine,
and allopurinol are all candidates for mitochondrial ROS modulators (Ishimoto & Inagi,
2016). The SIRT 1 activator resveratrol improves mitochondrial function and reduces
oxidative stress (Wang et al., 2015); clinical trials have been planned to investigate usage of
these modulators in patients with CKD. The present study as well as previous reports has
highlighted possible metabolic therapies for CKD.
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This study aimed to characterize one CKD model and the imposed study limitations
should be stated. Data on other CKDmodels were not examined in this study. Metabolome
analyses are a snapshot of changes; hence, the flow of metabolites was an estimation.
Microarray analysis was not performed, and gene expression was measured by quantitative
reverse transcription-polymerase chain reaction (RT-PCR). Therefore, pathway analysis,
such as KEGG, could not be performed in the present study. We analyzed the whole kidney
including tubules and glomeruli; therefore, we could not isolate the part of the kidney
undergoing the metabolic change. In addition, this study was observational and we did not
intervene in this model. Therefore, another set of experiments is needed to clarify whether
the metabolic changes is the cause or the consequence of kidney injury. However, this
model is still useful for preclinical studies since there is an increasing recognition that the
kidney plays an important role in complex inter-organ communication, which affects the
development of cardiovascular diseases.
CONCLUSIONS
DS rats fed anHSdiet are deemed a suitablemodel ofCKD.Gene expression andmetabolites
related to energy metabolism and mitochondria in the kidney significantly changed in DS
rats with hypertension in accordance with the progression of renal injury.
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